I have a suspicion about some of the background to the current Fiasp drama, where Novo seems to have been pressured to remove Fiasp from PBS listing. Stories are rarely simple. I don’t know this is the complete story, but I’ll try to stick to recounting known facts! This is a potted history of one …
I’ve had a few people ask whether PBS was actually going to de-list Fiasp. None of us wanted it to be real. They have now quietly made the announcement, buried within the monthly list of changes.
I’ve been spending this week in Berlin attending the ATTD 2023 conference. as part of the #dedoc˚ voices. It’s only half done so far. There’s a flood of presentations to attend, study results to absorb, and literally thousands of other people to talk to. It’s very hectic. But in the background I’ve become aware of …
It used to be that inside every packet of medicine there was a printed sheet with information about the drug. What it was, what it contained, what it was for, how to use it, possible side-effects to watch out for, how to store it safely, etc. Often this is printed on very thin paper to …
This is a repeat of my 2020 Safety Net article, updated with the new 2021 costs. This is of course only relevant to Australia. It’s not cheap having chronic health conditions and constantly needing medication. There are some government concessions available beyond the standard PBS subsidy, but we need to take charge and make sure …
Lantus is a long-acting basal insulin which has been around since 2000. That’s about to change, but don’t panic. Essentially it’s just a name change. History Lantus is a U100 form of insulin glargine, made by Sanofi. Its patent protection eventually ran out, so new versions started appearing from other companies. Lilly (who also make Humalog) …